Advertisement

AAPS PharmSciTech

, Volume 19, Issue 7, pp 3249–3257 | Cite as

Simultaneously Improving Mechanical, Formulation, and In Vivo Performance of Naproxen by Co-Crystallization

  • Nasir Abbas
  • Sumera Latif
  • Hafsa Afzal
  • Muhammad Sohail Arshad
  • Amjad Hussain
  • Saleha Sadeeqa
  • Nadeem Irfan Bukhari
Research Article
  • 117 Downloads

ABSTRACT

Naproxen (NAP), an anti-inflammatory drug belonging to class II of Biopharmaceutic Classification System, has low aqueous solubility and dissolution rate which limit its oral bioavailability. The focus of this investigation was to assess the impact of co-crystallization in improving the physico-mechanical and in vivo performance of NAP. NAP was co-crystallized using nicotinamide as a co-former employing liquid-assisted grinding method and characterized by intrinsic dissolution rate, DSC, and PXRD. Prepared co-crystal exhibited improved physicochemical and mechanical properties. Mechanical behavior of NAP and developed co-crystal was analyzed by drawing tabletability curves. Over the entire range of used compaction pressure, NAP showed poor tensile strength (< 2 MPa) which resulted in lamination and capping in some tablets. In contrast, tensile strength of co-crystal gradually increased with pressure and was ~ 1.80 times that of NAP at 5000 psi. Intrinsic dissolution profile of co-crystal showed a more than five and twofold faster dissolution than NAP in 0.1 M HCl and phosphate buffer pH 7.4 at 37°C. In addition, formulation of co-crystal powder into tablets by direct compression demonstrated enhanced dissolution profiles (~ 43% in 0.1 M HCl and ~ 92% in phosphate buffer pH 7.4) in comparison to a marketed product, Neoprox (~ 25 and ~ 80%) after 60 min. In a single dose oral exposure study conducted in sheep, co-crystal showed more than 1.5-fold increase in AUC and Cmax. In conclusion, co-crystals of NAP illustrated better tabletability, in vitro and in vivo performance.

KEY WORDS

naproxen co-crystal intrinsic dissolution tensile strength bioavailability 

Notes

Acknowledgements

The authors present their acknowledgement to Higher Education Commission (HEC) of Pakistan for provision of funds (NRPU-3535) for the current study to Punjab University College of Pharmacy, Punjab University, Lahore. We also acknowledge Abdul Muqeet Khan, Lecturer University of Veterinary and Animal Sciences for his help in bioavailability studies.

Compliance with Ethical Standards

Conflict of Interest

We report no declaration of interest.

References

  1. 1.
    Aitipamula S, Wong AB, Chow PS, Tan RB. Pharmaceutical cocrystals of ethenzamide: structural, solubility and dissolution studies. CrystEngComm. 2012;14:8515–24.  https://doi.org/10.1039/C2CE26325D.CrossRefGoogle Scholar
  2. 2.
    Banerjee R, Bhatt PM, Ravindra NV, Desiraju GR. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst Growth Des. 2005;5:2299–309.  https://doi.org/10.1021/cg050125l.CrossRefGoogle Scholar
  3. 3.
    Good DJ, Nr R-H. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 2009;9:2252–64.  https://doi.org/10.1021/cg801039j.CrossRefGoogle Scholar
  4. 4.
    Blagden N, De Matas M, Gavan P, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007;59:617–30.  https://doi.org/10.1016/J.addr.2007.05.011.CrossRefPubMedGoogle Scholar
  5. 5.
    Sheth AR, Grant DJ. Relationship between the structure and properties of pharmaceutical crystals. KONA Powder Part J. 2005;23:36–48.  https://doi.org/10.14356/kona.2005008.CrossRefGoogle Scholar
  6. 6.
    Khankari RK, Grant DJ. Pharmaceutical hydrates. Thermochim Acta. 1995;248:61–79.  https://doi.org/10.1016/0040-6031(94)01952-D.CrossRefGoogle Scholar
  7. 7.
    Tong HH, Chow AS, Chan H, Chow AH, Wan YK, Williams ID, et al. Process induced phase transformation of berberine chloride hydrates. J Pharm Sci. 2010;99:1942–54.  https://doi.org/10.1002/jps.21983.CrossRefPubMedGoogle Scholar
  8. 8.
    Arora KK, Zaworotko MJ. Pharmaceutical co-crystals: a new opportunity in pharmaceutical science for a long-known but little studied class of compounds. Poly Pharm solids. 2009;2:281–313.Google Scholar
  9. 9.
    Vishweshwar P, Mamahon JA, Zaworotko MJ. Pharmaceutical co-crystals. J Pharm Sci. 200;95:499–516.  https://doi.org/10.1002/jps.20578.CrossRefGoogle Scholar
  10. 10.
    Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodríguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453:101–25.  https://doi.org/10.1016/j.ijpharm.2012.10.043.CrossRefPubMedGoogle Scholar
  11. 11.
    Gao Y, Gao J, Liu Z, Kan H, Zu H, Sun W, et al. Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil–saccharin and adefovir dipivoxil–nicotinamide cocrystals. Int J Pharm. 2012;438:327–35.  https://doi.org/10.1016/j.ijpharm.2012.09.027.CrossRefPubMedGoogle Scholar
  12. 12.
    Vangala VR, Chow PS, Tan RB. Characterization, physicochemical and photo-stability of a co-crystal involving an antibiotic drug, nitrofurantoin, and 4-hydroxybenzoic acid. CrystEngComm. 2011;13:759–62.  https://doi.org/10.1039/C0CE00772B.CrossRefGoogle Scholar
  13. 13.
    Perumalla SR, Sun CC. Improved solid-state stability of salts by cocrystallization between conjugate acid–base pairs. CrystEngComm. 2013;15:5756–9.  https://doi.org/10.1039/C3CE40593A.CrossRefGoogle Scholar
  14. 14.
    McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS, et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res. 2006;23:1888–97.  https://doi.org/10.1007/s11095-006-9032-3.CrossRefPubMedGoogle Scholar
  15. 15.
    Ullah M, Hussain I, Sun CC. The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance. Drug Dev Ind Pharm. 2016;42:969–76.  https://doi.org/10.3109/03639045.2015.1096281.CrossRefPubMedGoogle Scholar
  16. 16.
    Karki S, Friščić T, Fábián L, Laity PR, Day GM, Jones W. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol. Adv Mater. 2009;21:3905–9.  https://doi.org/10.1002/adma.200900533.CrossRefGoogle Scholar
  17. 17.
    Maeno Y, Fukami T, Kawahata M, Yamaguchi K, Tagami T, Ozeki T, et al. Novel pharmaceutical cocrystal consisting of paracetamol and trimethylglycine, a new promising cocrystal former. Int J Pharm. 2014;473:179–86.  https://doi.org/10.1016/j.ijpharm.2014.07.008.CrossRefPubMedGoogle Scholar
  18. 18.
    Sun CC, Hou H. Improving mechanical properties of caffeine and methyl gallate crystals by cocrystallization. Cryst Growth Des. 2008;8:1575–9.  https://doi.org/10.1021/cg700843s.CrossRefGoogle Scholar
  19. 19.
    Chowhan Z. pH-solubility profiles of organic carboxylic acids and their salts. J Pharm Sci. 1978;67:1257–60.  https://doi.org/10.1002/jps.2600670918.CrossRefPubMedGoogle Scholar
  20. 20.
    Akbari J, Enayatifard R, Saeedi M, Morteza-Semnani K, Rajabi S. Preparation, characterization, and dissolution studies of naproxen solid dispersions using polyethylene glycol 6000 and labrafil M2130. Pharm Biomed Res. 2015;1:44–53.  https://doi.org/10.18869/acadpub.pbr.1.2.44.CrossRefGoogle Scholar
  21. 21.
    Neurohr C, Revelli A-L, Billot P, Marchivie M, Lecomte S, Laugier S, et al. Naproxen–nicotinamide cocrystals produced by CO2 antisolvent. J Supercrit Fluids. 2013;83:78–85.  https://doi.org/10.1016/j.supflu.2013.07.008.CrossRefGoogle Scholar
  22. 22.
    Ando S, Kikuchi J, Fujimura Y, Ida Y, Higashi K, Moribe K, et al. Physicochemical characterization and structural evaluation of a specific 2: 1 cocrystal of naproxen–nicotinamide. J Pharm Sci. 2012;101:3214–21.  https://doi.org/10.1002/jps.23158.CrossRefPubMedGoogle Scholar
  23. 23.
    Tumanova N, Tumanov N, Robeyns K, Filinchuk Y, Wouters J, Leyssens T. Structural insight into cocrystallization with zwitterionic co-formers: cocrystals of S-naproxen. CrystEngComm. 2014;16:8185–96.  https://doi.org/10.1039/c4ce00353e.CrossRefGoogle Scholar
  24. 24.
    Thenge RR, Patond VB, Adhao VS, Ajmire PV, Barde LN, Mahajan NM, et al. Preparation and characterization of cocrystals of Diacerein. Indonesian J Pharm. 2017;28:34–41.  https://doi.org/10.14499/indonesianjpharm28iss1pp34.CrossRefGoogle Scholar
  25. 25.
    Zhang Y, Huo M, Zhou J, Zou A, Li W, Yao C, et al. DDSolver: an add-in program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263–71.  https://doi.org/10.1208/s12248-010-9185-1.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Latif S, Abbas N, Hussain A, Arshad MS, Bukhari NI, Afzal H, et al. Development of paracetamol-caffeine co-crystals to improve compressional, formulation and in-vivo performance. Drug Dev Ind Pharm. 2018;44:1099–108.  https://doi.org/10.1080/03639045.2018.1435687.CrossRefPubMedGoogle Scholar
  27. 27.
    Yilmaz B, Asci A, Erdem AF. HPLC method for naproxen determination in human plasma and its application to a pharmacokinetic study in Turkey. J Chromatogr Sci. 2013;52:584–9.  https://doi.org/10.1093/chromsci/bmt080.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Prog Biomed. 2010;99:306–14.  https://doi.org/10.1016/j.cmpb.2010.01.007.CrossRefGoogle Scholar
  29. 29.
    Friščić T, Childs SL, Rizvi SA, Jones W. The role of solvent in mechanochemical and sonochemical cocrystal formation: a solubility-based approach for predicting cocrystallisation outcome. CrystEngComm. 2009;11:418–26.  https://doi.org/10.1039/B815174A.CrossRefGoogle Scholar
  30. 30.
    Ross S, Lamprou D, Douroumis D. Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies. Chem Commun. 2016;52:8772–86.CrossRefGoogle Scholar
  31. 31.
    Douroumis D, Ross SA, Nokhodchi A. Advanced methodologies for cocrystal synthesis. Adv Drug Deliv Rev. 2017;117:178–95.  https://doi.org/10.1016/j.addr.2017.07.008.CrossRefPubMedGoogle Scholar
  32. 32.
    Ullah M, Ullah H, Murtaza G, Mahmood Q, Hussain I. Evaluation of influence of various polymers and phase behavior of carbamazepine-succinic acid cocrystal in matrix tablets. Biomed Res Int. 2015;59:1–10.  https://doi.org/10.1016/J.addr.2007.05.011.CrossRefGoogle Scholar
  33. 33.
    Childs S, Hardcastle K. Co-crystals of piroxicam with carboxylic acids. Cryst Growth Des. 2007;7:1291–304.  https://doi.org/10.1021/cg060742p.CrossRefGoogle Scholar
  34. 34.
    Pagire SK, Jadev N, Vangala VR, Whiteside B, Paradkar A. Thermodynamic investigation of carbamazeoine-saccharin co-crystal polymorph. J Pharm Sci. 2017;106:2009–14.  https://doi.org/10.1016/j.xphs.2017.04.017.CrossRefPubMedGoogle Scholar
  35. 35.
    Karagianni A, Malamatari M, Kachrimanis K. Pharmaceutical cocrystals: new solid phase modification approaches for the formulation of APIs. Pharmaceutics. 2018;10:1–30.  https://doi.org/10.3390/pharmaceutics10010018.CrossRefGoogle Scholar
  36. 36.
    Katritzky AR, Jain R, Lomaka A, Petrukhin R, Maran U, Karelson M. Perspective on the relationship between melting points and chemical structure. Cryst Growth Des. 2001;1:261–5.  https://doi.org/10.1021/cg010009s.CrossRefGoogle Scholar
  37. 37.
    Simperler A, Watt SW, Bonnet PA, Jones W, Motherwell WS. Correlation of melting points of inositols with hydrogen bonding patterns. CrystEngComm. 2006;8:589–600.  https://doi.org/10.1039/B606107A.CrossRefGoogle Scholar
  38. 38.
    Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009;9:2950–67.  https://doi.org/10.1021/cg900129f.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kerr HE, Softley LK, Suresh K, Hodgkinson P, Evans IR. Structure and physicochemical characterization of a naproxen–picolinamide cocrystal. Acta Crystallogr Sec C: Struct Chem. 2017;73:168–75.  https://doi.org/10.1107/S2053229616011980.CrossRefGoogle Scholar
  40. 40.
    Rajurkar VG, Gite RD, Ghawate VB. Development of naproxen co crystal formation: an efficient approach to enhance aqueous solubility. Anal Chem Lett. 2015;5:229–238. doi: https://doi.org/10.1080/22297928.2015.1128850 CrossRefGoogle Scholar
  41. 41.
    Wolff S, Grimwood D, McKinnon J, Turner M, Jayatilaka D, Spackman M. Crystal explorer ver. 3.1. University of Western Australia, Perth, Australia. 2013.Google Scholar
  42. 42.
    Ilić I, Govedarica B, Srčič S. Deformation properties of pharmaceutical excipients determined using an in-die and out-die method. Int J Pharm. 2013;446:6–15.  https://doi.org/10.1016/j.ijpharm.2013.02.001.CrossRefPubMedGoogle Scholar
  43. 43.
    Patel S, Kaushal AM, Bansal AK. Effect of particle size and compression force on compaction behavior and derived mathematical parameters of compressibility. Pharm Res. 2007;24:111–24.  https://doi.org/10.1007/s11095-006-9129-8.CrossRefPubMedGoogle Scholar
  44. 44.
    Tye CK, Sun CC, Amidon GE. Evaluation of the effects of tableting speed on the relationships between compaction pressure, tablet tensile strength, and tablet solid fraction. J Pharm Sci. 2005;94:465–72.  https://doi.org/10.1002/jps.20262.CrossRefPubMedGoogle Scholar
  45. 45.
    Chow SF, Chen M, Shi L, Chow AH, Sun CC. Simultaneously improving the mechanical properties, dissolution performance, and hygroscopicity of ibuprofen and flurbiprofen by cocrystallization with nicotinamide. Pharm Res. 2012;29:1854–65.  https://doi.org/10.1007/s11095-012-0709-5.CrossRefPubMedGoogle Scholar
  46. 46.
    Joiris E, Di Martino P, Berneron C, Guyot-Hermann A-M, Guyot J-C. Compression behavior of orthorhombic paracetamol. Pharm Res. 1998;15:1122–30.  https://doi.org/10.1023/A:1011954800246.CrossRefPubMedGoogle Scholar
  47. 47.
    Saritha D, Bose PSC, Reddy PS, Madhuri G, Nagaraju R. Improved dissolution and micromeritic properties of naproxen from spherical agglomerates: preparation, in vitro and in vivo characterization. Braz J Pharm Sci. 2012;48:683–90.  https://doi.org/10.1590/S1984-82502012000400010.CrossRefGoogle Scholar
  48. 48.
    Rahman Z, Agarabi C, Zidan AS, Khan SR, Khan MA. Physico-mechanical and stability evaluation of carbamazepine cocrystal with nicotinamide. AAPS PharmSciTech. 2011;12:693–704.  https://doi.org/10.1208/s12249-011-9603-4.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Sun CC. Decoding powder tabletability: roles of particle adhesion and plasticity. J Adhes Sci Technol. 2011;25:483–99.  https://doi.org/10.1163/016942410X525678.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.University College of PharmacyUniversity of the PunjabLahorePakistan
  2. 2.Institute of PharmacyLahore College for Women UniversityLahorePakistan
  3. 3.Department of PharmaceuticsBahauddin Zakariya UniversityMultanPakistan

Personalised recommendations